Baclofen formulations and methods for making same
Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms.
1. An injectable baclofen solution, the solution comprising:
baclofen in a concentration greater than 2 mg/mL; sulfate or phosphate in a concentration of between 10 mM and 25 mM, wherein the solution has an ionic strength equivalent of between 1, the solution c.4 M NaCl and 1.6 M NaCl comprising less than 1.3% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 30 days of storage at room temperature, wherein the solution has a pH between about 5.5 and 6.5.
2. The injectable solution of claim 1 , wherein solution is sterilized and comprises 0.2% to 1.1% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 30 days of storage at room temperature.
3. The injectable solution of claim 1 , wherein the solution is sterilized and comprises 0.2% to 1.1% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 6 months of storage at room temperature.
4. The injectable solution of claim 1 , wherein the solution comprises 0.2% to 0.4% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 6 months of storage at room temperature.
5. The injectable solution of claim 1 , wherein the baclofen is at a concentration between 2.1 mg/mL and 7 mg/mL.
6. The injectable solution of claim 1 , wherein the solution consists essentially of the baclofen, the sulfate or phosphate, sodium ion, and water.
7. The injectable solution of claim 1 , further comprising NaCl, wherein the NaCl is present in an amount to provide the solution with an ionic strength equivalent to 1.5 M NaCl.
8. The injectable solution of claim 7 , wherein the solution consists essentially of the baclofen, the sulfate or phosphate, sodium ion, chloride ion, and water.
9. The injectable solution of claim 1 , wherein the sulfate is derived from Na 2 SO 4 .
10. The injectable solution of claim 1 , wherein the phosphate is derived from NaH 2 PO 4 .
11. The injectable solution of claim 1 , wherein the solution has a pH of 6.0.
12. The injectable solution of claim 1 , wherein the solution comprises 0.2% to 0.4% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 30 days of storage at room temperature.
13. A method for preparing an injectable baclofen solution of claim 1 , the method comprising:
dissolving baclofen in aqueous solvent, selected from water, a saline solution, water containing phosphate or sulfate, or a saline solution containing sulfate or phosphate, to generate an initial solution
adjusting the pH of the initial solution to between 5.5 and 6.2 to produce a pH adjusted solution; and
steam sterilizing the pH adjusted solution to achieve a sterility assurance level of 1×10 6 , producing a the injectable baclofen solution.
14. The method of claim 13 , wherein the steam sterilizing comprises sterilizing to an F° for at least 15 minutes at 121° C.
15. The method of claim 13 , wherein the terminally sterilized solution, after storage of 6 months at room temperature, has a pH of between 5.5 and 6.2 and has less than 1.3% of 4-CPP.
16. The method of claim 13 , wherein the initial solution further comprises NaCl.
17. The method of claim 16 , wherein the initial solution comprises NaCl in an amount that provides the initial solution with an ionic strength equivalent to 1.4 M NaCl and 1.6 M NaCl.
18. The method of claim 13 , wherein the terminally sterilized solution has less than 1% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on the concentration of baclofen added to the initial solution.
19. The method of claim 13 , wherein the terminally sterilized solution, after storage of 6 months at room temperature, has less than 1% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) based on the concentration of baclofen added to the initial solution.
20. The method of claim 13 , wherein the terminally sterilized solution, after storage of 6 months at room temperature, has a pH of between 5.5 and 6.2.
21. The method of claim 13 , wherein adjusting the pH of the initial solution comprises adjusting the pH to between 5.5 and 6.0.
22. The method of claim 13 , wherein the concentration of baclofen in the initial solution is about 2 mg/mL and wherein adjusting the pH of the initial solution comprises adjusting the pH to between 5.5 and 6.2.
23. The method of claim 13 , wherein adjusting the pH of the initial solution comprises adjusting the pH with HCl, H 2 SO 4 , H 3 PO or NaOH.
24. A method for preparing solution of claim 1 , the method comprising:
adjusting a pH of baclofen in an aqueous solvent to between about 5.5 to 6.5 to form a pH adjusted solution, the aqueous solvent comprising water, a saline solution, water containing phosphate, sulfate, potassium, magnesium or a saline solution containing sulfate, phosphate, potassium or magnesium; and
steam sterilizing the pH adjusted solution to achieve a sterility assurance level of 1×10 6 so as to form a terminally sterilized solution.
25. The method of claim 24 , wherein the terminally sterilized solution comprises about 0.2% to about 1.1% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 30 days of storage at room temperature.
26. The method of claim 24 , wherein the terminally sterilized solution comprises about 0.2% to about 0.4% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 6 months of storage at room temperature.
27. The method of claim 24 , wherein the concentration of baclofen in the pH adjusted solution is between 2 mg/mL and 7 mg/mL and the baclofenis D-baclofen.
28. The method of claim 24 , wherein the concentration of baclofen in the pH adjusted solution is between 2 mg/mL and 7 mg/mL and the baclofen is DL-baclofen racemate.
29. A method of reducing formation of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) in an injectable baclofen solution of claim 1 , the method comprising:
adjusting a pH of baclofen in an aqueous solvent to between about 5.5 to 6.5 to form a pH adjusted solution, the aqueous solvent comprising water, a saline solution, water containing phosphate, sulfate, potassium, magnesium or a saline solution containing sulfate, phosphate, potassium or magnesium, and
steam sterilizing the pH adjusted solution to achieve a sterility assurance level of 1×10 6 so as to form a terminally sterilized solution.
30. The method of claim 29 , wherein the terminally sterilized solution comprises about 0.2% to about 0.8% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 30 days of storage at room temperature.
31. The method of claim 29 , wherein the terminally sterilized solution comprises about 0.2% to about 0.4% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 6 months of storage at room temperature.
32. The method of claim 29 , wherein the concentration of baclofen in the pH adjusted solution is between 2 mg/mL and 7 mg/mL and the baclofen is D-baclofen.
33. The method of claim 29 , wherein the concentration of baclofen in the pH adjusted solution is between 2 mg/mL and 7 mg/mL and the baclofen is DL-baclofen racemate.
34. An injectable baclofen solution, the solution consisting of:
baclofen in a concentration greater than 2 mg/mL; sulfate or phosphate in a concentration of between 10 mM and 25 mM, wherein the solution has an ionic strength equivalent of between 1.4 M NaCl and 1.6 M NaCl, the solution comprising less than 1.3% of 4-(4-chlorophenyl)-2-pyrrolidinone (4-CPP) after at least 30 days of storage at room temperature, wherein the solution has a pH between about 5.5 and 6.5.